loidosis syndrome (8) , it seemed likely that isolation and identification of the cerebrovascular amyloid fibril protein in Alzheimer's disease would make possible the identification of a unique amyloid fibril precursor protein in the serum of these patients. This in turn would lead to a specific diagnostic serum test for Alzheimer's disease.
MATERIALS AND METHODS
Amyloid Fibril Concentration: Human brains obtained at autopsy were frozen at -70°C. Histological sections were taken, stained for amyloid and only those with extensive cerebrovascular amyloidoses were selected for amyloid fibril isolation. Age matched normal brains were used for controls. The meninges were stripped, and gross cortex contaminants removed. The tissue was homogenized in 0.09% sodium chloride-0.1% sodium azide and the homogenate centrifuged in a Sorvall RC-5B (DuPont Instruments) at 12,500 x g for 60 min. at 4°C. The supernatant was discarded. The resultant pellet was made up of two visually distinct layers. The thin brownish top layer was enriched in amyloid protein as monitored by polarization microscopy after Congo red staining. The layers were separated by dissection of the frozen pellet. A second homogenization of the lower layer yielded a significant second crop of amyloid protein. The amyloid enriched top layer was homogenized in 0.05 M TRIS-HCI, 3 mMNaN 3, 0.01 mM CaCI2, pH 7.5 buffer to make an approximate 4% solution (w/v). Solid collagenase (EC 3.4.24;3, Sigma Chemical type I) was added in a i:i00 ratio (weight enzyme: weight pellet) and the resultant mixture was incubated in a Dubnoff shaker at 37°C for 8 hrs. The digestion by collagenase was monitered by Congo red staining with polarization microscopy and by x-ray crystallography (2) . After the digestion was completed, the mixture was centrifuged in a Beckman L5-50B ultracentrifuge at 105,000 x g for 60 min. at 4°C. The supernatant was discarded and the pellet frozen at -20°C.
Protein Extraction: The collagenase-treated pellet was solubilized in 6 M guanidine-HC1, 0.i M TRIS-HCI, 25 ~M dithiotheitol, 0.34 m~ EDTA, pH 8.0 (22% w/v) and stirred at room temperature for 48 hrs. After 48 hrs. the solution was centrifuged in a Beckman L5-50B ultracentrifuge at 105,000 x g for 60 min. at 4°C. The pellet was separated from the supernatant. The supernatant was placed into I000 molecular wt. cut off dialysis tubing (Spectra/Por 6, Fisher Scientific) and dialyzed, lyophilized and the resulting powder stored dessicated at -70°C.
SDS-Urea Polyacrylamide Gel Electrophoresis (SDS-urea PAGE): SDS-urea PAGE was done by the Laemmli system (ii) modified only by the addition of 8 M urea in the stacking and resolving gel. Slab gels (15%) were made 0.75 rmn thick and run at i0 mA constant current. After electrophoresis, gels were stained with Coomassie Brilliant Blue R.
G-100 Sephade x Column Chromat0$raphy: The procedure was identical to that employed previously (12) using a 2.5 x i00 cm G-IO0 calibrated Sephadex column (Pharmacia) equilibrated with 5 M guanidine-HCl, 1.0 N acetic acid with 40 mg of protein applied. The column was calibrated with cytochrome C (horse heart), 12,384 M r and glucago n, 3,485 M r . The protein elution profile was monitored at 280 nm with a Beckman 35 spectrophotometer. The protein peak centered at 4,200 M r was pooled and dialyzed exhaustively against deionized water, lyophilized and stored dessicated at -70°C.
High Performance Liquid Chromatography (HPLC): One hundred ~g of the lyophilized protein from peak fractions of the Sephadex column was solubilized into 50 ~i of 88% formic acid. This was injected into a Waters HPLC system. The mobile phase was: solvent A: 0.1% trifluoroacetic acid/H20, solvent B: 100% acetoni-trile. The gradient was linear from 10% to 50% solvent B over 60 min. Flow rate was 0.8 ml/min, and the protein peaks were detected at 229 nm with 2.0 AUFS. The stationary phase used was a Vydac 214TP54 C 4 peptide column. Two major protein peaks were found (Fig. i) . One at 35% solvent B and the other at 36% solvent B. These protein peaks were pooled separately, lyophilized and stored at -70°C. For samples that were prepared for amino acid analysis, i0 D1 of 20% sodium dodecyl sulfate was added before lyophilization.
Amino Acid Analysis: Samples to be analyzed for amino acid composition were hydro lyzed with 6 M HCI in vacuo at IIOOC for 24 hrs. After 24 hrs. the samples were dried in a vacuum chamber with a NaOH trap. The dried samples were solubilized in pH 2.2 citrate buffer and injected into a Beckman I18C Automatic Amino Acid Analyzer for analysis. Norleucine was used for the internal standard.
Amino Acid Sequencing: Samples were dissolved in heptafluorobutyric acid and loaded in a Beckman 890C spinning cup sequencer. The collected anilothiazolone amino acids were converted to phenylthiohydantoin amino acids (PTH-amino acids) with 1 N HCI/MeOH at 50°C for i0 minutes. The PTH-amino acids were dried and redissolved in MeOH. The PTH-amino acids were analyzed on a Beckman 322 HPLC system fitted with a ETH-Permaphase guard column and a IBM 6 ~ CN column in line. The eluent was monitored at 254 nm.
RESULTS AND DISCUSSION
By polarization microscopy after staining with Congo red the presence of amyloid fibers can readily be demonstrated by their green polarization color in the isolated meningeal vessels of Alzheimer's disease patients. With this property as our marker we have designed a protocol that affords isolation of a fraction that is highly enriched in amyloid fibers. It appears that collagen is the major contaminant in the crude homogenates. Initial experiments with collagenase showed that the amyloid fibers are resistent to this protease. 
PERCENT ACETONITRILE
HPLC of cerebrovascular amyloid fibril protein B from a patient with Alzheimer's disease, previously isolated on Sephadex G-100, reveals two major protein peaks (B 1 and Bg), each of similar amino acid composition and identic~l amin5-terminal amino acid sequence (Table 2) .
centered at 4,200 daltons. Because of its uniqueness to amyloid fibril preparations, it was assumed, as shown in numerous, previous studies (4), to be a major protein constituent of the amyloid fibrils. High performance liquid chromatography fractionated two peaks from the G-100 preparation (Fig.l ) and these were found to have almost identical amino acid compositions (Table i) .
Two other cases of Alzheimer's disease gave identical HPLC profiles.
The vast majority of amyloid fibrils in the systemic diseases are created from a serum protein precursor by proteolysis, probably by the lyosomal complement of phagocytes (4) . The finding of proteins fractionated into two peaks by HPLC suggests that one may represent a proteolytic cleavage product of the other. The proteins obtained from these two peak fractions were submitted to automated amino acid sequencing to residue 24 ( Table 2 ). The partial sequences of the two peaks were identical. A computer search of this sequence reveals no homology with any protein sequenced thus far including a human gamma trace serum protein found to constitute the fibrils of a familial Icelandic cerebrovascular amyloidosis (8) . This protein, therefore, appears to be a biologic marker for the cerebrovascular amyloid fibril component of Alzheimer's disease. The significance of this finding is that when monoclonal antibodies are raised to the amyloid fibril protein reported here, these should detect an antigenically related protein in Alzheimer's disease patients' sera. If the Table 2 . Sequence of Cerebrovascular Amyloid Protein NH2-Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Gln-ValHis-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val---COOH serum protein is also unique to this condition, a diagnostic serum (e.g. radioimmunoassay) test for Alzheimer's disease can be devised. This study is in progress. If adult Down's syndrome individuals also are found to have this cerebrovascular amyloid protein (i0), they will represent the first predictable model for the study of the pathogenesis of Alzheimer's disease.
